Literature DB >> 9862095

Role of echocardiography in systemic arterial embolism. A review with recommendations.

H Egeblad1, K Andersen, J Hartiala, A Lindgren, R Marttila, P Petersen, A Roijer, D Russell, B Wranne.   

Abstract

The ability of echocardiography to diagnose sources of embolism and the role of the examination in the prediction of thromboembolism are reviewed. In addition, the yield of transthoracic (TTE) and transoesophageal echocardiography (TEE) is analysed in patients with suspected embolism and guidelines are proposed for performing echocardiography in this setting. In general, echocardiography is reliable for diagnosing sources of embolism and this applies in particular to TEE in the case of atrial, valvular, and aortic abnormalities. However, the method is useful for predicting embolism in a few cases only. There is a substantial risk in the event of mobile or protruding thrombi, but screening for these and other markers of thromboembolism seems to be unproductive in most groups of risk patients. Yet, in the presence of atrial fibrillation, echocardiography may be helpful in defining patients with an otherwise normal heart and low risk of embolism--and in defining the relatively rare patient with a clinically low-risk profile but moderate-to-severe left ventricular systolic dysfunction and a high risk of embolism. TEE-guided conversion of atrial fibrillation without weeks of preceding anticoagulation may prove useful, after further investigation. The risk of embolism in relation to the size and mobility of valvular vegetations has remained controversial. In patients with suspected recent embolism, TTE results in less than 5% new therapeutic consequences. In those with a normal TTE, the yield of TEE seems to be equally low. We therefore recommend a selective strategy: TTE and TEE can be omitted when a cardiac source of embolism appears from the clinical setting and in most patients with an obvious predisposition to cerebrovascular disease. However, in the latter cases TTE should be performed if indicated by the clinical situation, e.g. in the presence of fever and murmur. TTE is also recommended when there are no obvious markers of primary vascular disease. To preclude very rare sources of embolism (e.g. atrial thrombi despite sinus rhythm), supplementary TEE is recommended in younger patients in whom primary vascular disease is very unlikely. The diagnosis by TEE of common conditions such as atrial septal aneurysms and patent foramen ovale cannot, however, be taken as proof of the mechanism of a systemic arterial occlusive event; thus it is difficult to change therapy on the basis of such diagnoses.

Entities:  

Mesh:

Year:  1998        PMID: 9862095     DOI: 10.1080/14017439850139780

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  4 in total

Review 1.  Stroke in younger patients: the heart of the matter.

Authors:  P E Cotter; M Belham; P J Martin
Journal:  J Neurol       Date:  2010-07-11       Impact factor: 4.849

2.  Prevalence of Positive Troponin and Echocardiogram Findings and Association With Mortality in Acute Ischemic Stroke.

Authors:  Peter Wrigley; Jane Khoury; Bryan Eckerle; Kathleen Alwell; Charles J Moomaw; Daniel Woo; Mathew L Flaherty; Felipe De Los Rios la Rosa; Jason Mackey; Opeolu Adeoye; Sharyl Martini; Simona Ferioli; Brett M Kissela; Dawn O Kleindorfer
Journal:  Stroke       Date:  2017-04-05       Impact factor: 7.914

3.  Transoesophageal echocardiography in selecting patients for anticoagulation after ischaemic stroke or transient ischaemic attack.

Authors:  M Strandberg; R J Marttila; H Helenius; J Hartiala
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-07       Impact factor: 10.154

4.  Combined arterial and venous whole-body MR angiography with cardiac MR imaging in patients with thromboembolic disease--initial experience.

Authors:  Florian M Vogt; Peter Hunold; Christoph U Herborn; Stefan G Ruehm; Joerg Barkhausen; Knut Kroger
Journal:  Eur Radiol       Date:  2008-01-10       Impact factor: 5.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.